Alemtuzumab for the prevention and treatment of graft-versus-host disease

@article{Kanda2011AlemtuzumabFT,
  title={Alemtuzumab for the prevention and treatment of graft-versus-host disease},
  author={Junya Kanda and Richard D. Lopez and David Alan Rizzieri},
  journal={International Journal of Hematology},
  year={2011},
  volume={93},
  pages={586-593}
}

• Junya Kanda, Richard D. Lopez, David Alan Rizzieri
• Published in
  International journal of…
  2011
• DOI:10.1007/s12185-011-0802-2

Alemtuzumab is a humanized monoclonal antibody against the CD52 antigen, which is expressed on the surface of various hematopoietic cells such as B and T lymphocytes, and has been widely used for preventing acute graft-versus-host disease (GVHD) in allogeneic stem cell transplantation (SCT). Administration of 100 mg alemtuzumab before transplantation has resulted in a low incidence of acute GVHD in HLA-matched and mismatched transplantation from either related or unrelated donors. However… CONTINUE READING

View on Springer

Alternate Sources

Save to Library

Create Alert

Cite